Loading Now

Biocon Biologics sees diversified global expansion offsetting US localisation risks

Biocon Biologics sees diversified global expansion offsetting US localisation risks


The pro-localisation policy in the US will not impact Biocon Biologics’ revenue, noted Shreehas Tambe, CEO of Biocon Biologics.

The US, which contributes 40 per cent of the company’s revenue has a limited risk due to Biocon’s Biologics’s market diversification, coupled with the company’s strategy of hiring internationally, Tambe said. “In the US, we have a large workforce of Americans, and we operate as a local company,” he added.

The company has observed sustained growth in the Mediterranean and UK-Nordics clusters, he noted. Additionally, Biocon Biologics is experiencing positive traction in the Japanese and Australian markets through its commercial partner, the company said.

On trade tariffs, he stated that, “Our intent is to bring affordability and broaden access to patients in America. We believe the U.S. administration is also focused on lowering healthcare costs. In that sense, our exposure is limited, as our intent and objectives are well aligned.”

Quarter performance for Biologics

Biocon Biologics reported ₹2,289 crore in revenue for the Biosimilars segment, marking a 14 per cent year-on-year (YoY) growth on a like-for-like basis. Sequentially, profits increased by 5 per cent. R&D investments stood at ₹135 crore, accounting for 6 per cent of total revenue.

The oncology franchise witnessed a significant increase in demand, while insulin sales remained in the mid-to-high teens across all channels. In Europe, Biocon Biologics maintained stable market shares at a regional level, with strong uptake in key markets such as Germany and France, where the company holds double-digit market shares for products like Hulio.

Discussing the company’s debt strategy, Tambe stated, “We have structured our debt, including US dollar bond listed on the Singapore Stock Exchange. This $800 million bond, along with the $300 million refinancing of a syndicated loan, improved our liquidity, allowing us to focus on future business expansion.”

The pharma major reported a profit after tax (PAT) of ₹25 crore for the quarter ended December 31, a 96 per cent decline compared to ₹660 crore in the same quarter last year.

After adjusting for exceptional items, profit stood at ₹13 crore. The company stated that last year’s profits were attributed to a one-time gain from Bicara and income from Biocon Biologics’ partial divestment of the BFI business.





Source link

Post Comment